

Posting Date: July 8, 2021

Closing Date: July 22, 2021 11:30 a.m. ET

Reference Number: 21-044265

To: NCI Bid Board

From: Sharon Coles-Calloway  
NCI DCEG Purchasing Agent  
[coless@mail.nih.gov](mailto:coless@mail.nih.gov)

Subject: NCI Bid Board Posting – Feasibility Report: Etiology of lung cancer in never smokers and special exposure cohorts

The Integrative Tumor Epidemiology Branch (ITEB) employs molecular pathology, somatic and germline genomics, and epidemiology to identify environmental and germline risk factors for cancer. The mission of ITEB is to conduct large-scale, international epidemiological research on cancer etiology and progression through integrative analyses of risk factors and tissue profiling to inform prevention and clinical strategies.

Sherlock Lung is a research project funded by the National Cancer Institute (NCI) Intramural Research Program at the Division of Cancer Epidemiology and Genetics (DCEG) aiming to investigate the etiology and progression of lung cancer in never-smokers from the general population, as well as from populations with substantial levels of special exposures through: (1) an integrative genomic analysis, and (2) pathology, clinical, radiological and epidemiologic assessment.

The National Cancer Institute plans to assess the feasibility for a coordinating center to assemble existing biospecimens, images, and data from multiple sites in Nigeria as part of NCI's Sherlock Lung study. This work will include the delivery of a report on the feasibility to assemble biospecimens, images, and data and an initial batch of biospecimens, data, radiology images and reports, and pathology reports from up to 10 never-smoking lung cancer patients. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine if the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on July 22, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

The NCI Sherlock Lung study needs to assemble a substantial number of non-smoking lung cancer cases of African ancestry. Given the rarity of lung cancer in never-smokers, the paucity of pathology material and other related data particularly among populations of African ancestry, and the logistic challenges to collect samples in relevant geographic areas, NCI needs to assess the feasibility for a coordinating center to oversee the assembling of such biospecimens and data.

The Institute of Human Virology, Nigeria (IHVN) was established in 2004 and successfully implemented the U.S. Government's PEPFAR prevention, care, support, and treatment activities in Nigeria. It is currently a world-class platform for program, research, and training projects and activities in infectious and non-infectious disease in Nigeria, with

multidisciplinary staff including scientists, clinicians, laboratory scientists, allied health professions, and administrative staff. It is also a long-term key partner for NIH, CDC, WHO, Global Fund, and U.S. research universities in Nigeria. Located in the capital city of Abuja, IHVN provides leadership for regional offices and develops and maintains linkages within the country in support of the Nigerian Government's health sector strategic plans, including the National Cancer Control Program. Given the world-class research environment rare in this setting, a broad network of collaborations across the country, and a track record in successful international collaborations, IHVN presents a unique center to coordinate and oversee the collection of biospecimens and data from a large African population in developing country setting for Sherlock.

Attached Documents:

SF18

Statement of Work

FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (AUG 2019) is applicable and available in full text upon request

FAR Clause 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment

<b>REQUEST FOR QUOTATION (THIS IS NOT AN ORDER)</b>		THIS RFQ <input type="checkbox"/> IS <input type="checkbox"/> IS NOT A SMALL BUSINESS SET-ASIDE		PAGE OF PAGES
1. REQUEST NO.	2. DATE ISSUED	3. REQUISITION/PURCHASE REQUEST NO.	4. CERT. FOR NAT. DEF. UNDER BDSA REG. 2 AND/OR DMS REG. 1	RATING
5a. ISSUED BY			6. DELIVER BY (Date)	
5b. FOR INFORMATION CALL (NO COLLECT CALLS)			7. DELIVERY	
NAME		TELEPHONE NUMBER		<input type="checkbox"/> FOB DESTINATION <input type="checkbox"/> OTHER (See Schedule)
		AREA CODE	NUMBER	9. DESTINATION
8. TO:				
a. NAME		b. COMPANY		b. STREET ADDRESS
c. STREET ADDRESS				c. CITY
d.. CITY		e.. STATE	f.. ZIP CODE	d.. STATE e. ZIP CODE
10. PLEASE FURNISH QUOTATIONS TO THE ISSUING OFFICE IN BLOCK 5a ON OR BEFORE CLOSE OF BUSINESS (Date)		<b>IMPORTANT:</b> This is a request for information, and quotations furnished are not offers. If you are unable to quote, please indicate on this form and return it to the address in Block 5a. This request does not commit the Government to pay any costs incurred in the preparation of the submission of this quotation or to contract for supplies or services. Supplies are of domestic origin unless otherwise indicated by quoter. Any representations and/or certifications attached to this Request for Quotations must be completed by the quoter.		

**11. SCHEDULE (Include applicable Federal, State and local taxes)**

ITEM NO. (a)	SUPPLIES/SERVICES (b)	QUANTITY (c)	UNIT (d)	UNIT PRICE (e)	AMOUNT (f)

<b>12. DISCOUNT FOR PROMPT PAYMENT</b>	a. 10 CALENDAR DAYS (%)	b. 20 CALENDAR DAYS (%)	c. 30 CALENDAR DAYS (%)	d. CALENDAR DAYS
				NUMBER PERCENTAGE

NOTE: Additional provisions and representations  are  are not attached.

13. NAME AND ADDRESS OF QUOTER		14. SIGNATURE OF PERSON AUTHORIZED TO SIGN QUOTATION	15. DATE OF QUOTATION
a. NAME OF QUOTER			
b. STREET ADDRESS		16. SIGNER	
c. COUNTY		a. NAME (Type or print)	b. TELEPHONE
d. CITY		AREA CODE	
e. STATE f. ZIP CODE		c. TITLE (Type or print)	
		NUMBER	

# STATEMENT OF WORK (SOW)

## STATEMENT OF WORK

### 1.0 TITLE

Etiology of lung cancer in never smokers and special exposure cohorts

### 2.0 BACKGROUND

Sherlock Lung is a research project funded by the National Cancer Institute (NCI) Intramural Research Program at the Division of Cancer Epidemiology and Genetics (DCEG) aiming to investigate the etiology and progression of lung cancer in never-smokers from the general population, as well as from populations with substantial levels of special exposures through: (1) an integrative genomic analysis, and (2) pathology, clinical, radiological and epidemiologic assessment.

Current understanding of the molecular mechanisms of tumorigenesis is primarily based on research in population of European ancestry. However, increasing evidence shows that genomic profiles of cancer, including lung cancer, differ by ancestry. For example, a recent study demonstrated higher genetic instability and homologous recombination deficiency in lung squamous cell carcinoma tumors in African Americans compared to European Americans, it also found African American-specific copy-number-based arm-, focal- and gene-level recurrent features in lung cancer. The evidence highlight the need to understand the molecular landscape of lung cancer in population of African ancestry; such studies are currently under-represented and may have therapeutic implications. Further, besides genomic differences in lung cancer, exposure to risk factors for lung cancer in parts of the developing world where the majority of the population of African ancestry resides also differ substantially from other parts of the world. For example, in sub-Saharan Africa, only 40% of lung cancer deaths are attributable to tobacco smoking, compared to about 60% globally, and >80% in the United States. The evidence further suggests the need to investigate lung cancer etiology in never smokers in these populations. So far, we are unaware of any studies characterizing the genomic profile and etiology of lung cancer among never-smoking populations of African ancestry. Such efforts are further complicated by the wide geographic spread and the lack of research infrastructure in relevant geographic regions.

Given the rarity of lung cancer in never-smokers, the paucity of pathology material and other related data particularly among populations of African ancestry, and the logistic challenges to sample collection in relevant geographic areas, NCI needs a coordinating center to assemble existing biospecimens, images, clinical and epidemiologic data for lung cancer among never-smokers across multiple sites in Nigeria. These activities are essential to ensure the diverse and representative ancestry of the Sherlock Lung study.

### 2.1 OBJECTIVE

The purpose of the procurement is to fund the assessment of the feasibility for a coordinating center to assemble existing biospecimens, images, and data from multiple sites in Nigeria as part of NCI's Sherlock Lung study. This work will include the delivery of a report on the feasibility to assemble biospecimens, images, and data and an initial batch of biospecimens and data.

### 3.0 SCOPE

## STATEMENT OF WORK (SOW)

In support of the NCI's Sherlock Lung study, the contractor shall assess the feasibility to assemble existing biospecimens, images, and data from multiple sites in Nigeria. The vendor shall deliver a report on the feasibility to assemble biospecimens, images, and data to the NCI point of contact. To ensure the quality and integrity of the biospecimens and data, the contractor will also send an initial batch of biospecimens, images, and data from up to 10 never-smoker lung cancer patients to the designated NCI point of contact.

### 4.0 CONTRACT REQUIREMENTS/ AND PERSONNEL QUALIFICATIONS

The contractor shall:

- 4.1 Prepare a report on the feasibility as a coordinating center to assemble biospecimens, images, and clinical and epidemiologic data of never-smoking lung cancer cases from multiple sites in Nigeria. The report will include the following information by site: the available number of never-smoking lung cancer cases, the available number of fresh frozen tumor, normal, and blood tissues, FFPE tumor blocks, chest CT, PET, and x-ray images, and key clinical and epidemiological data, and the expected time frame to delivery the biospecimens and data. It will also include the expected challenges and suggestions for material and data collection.
- 4.2 Shipment of an initial batch of following biospecimens for up to 10 never-smoker lung cancer cases retrieved from sites to designated the laboratory:
  - a. Fresh frozen tumor tissue (T) >60% tumor cells, <20% necrosis. Multiple samples preferred. If from biopsies, 2 samples of 40 mg each.
  - b. Paired fresh frozen normal tissue (N), no tumor cells. Multiple samples preferred (4 normal specimens if possible). If biopsies, 2 samples of 40 mg each.
  - c. Blood (B) 500uL whole blood or buffy coat
  - d. FFPE blocks at least one from tumor center and one from tumor periphery to be sectioned.
  - e. Peri-diagnostic plasma (P), optimal  $\geq 7$ ml, minimum  $\geq 3$  ml
- 4.3 Deliver an initial batch of following de-identified data for each never-smoker lung cancer case retrieved from sites to NCI contact person:
  - a. Epidemiologic data in spreadsheets: variables shall include but are not limited to demographics, BMI, occupational and environmental exposures, residential history, family history, medical history and history of lung diseases or other infections.
  - b. Clinical data in spreadsheets: variables shall include but are not limited to clinical stage, histology, grade, survival, recurrence, metastasis and other treatment categories.
  - c. All available chest CT, PET, and x-ray images (if CT and/or PET available, x-ray not required) for each case along with de-identified radiology reports or information abstracted from radiology reports. The images should be transferred via a secure web portal or shipped in CD or DVD.
  - d. Pathology reports or information abstracted from pathology reports, delivered electronically or via shipment.

### 5.0 TYPE OF ORDER

*This is a firm fixed price purchase order.*

## STATEMENT OF WORK (SOW)

### 6.0 PERIOD OF PERFORMANCE

The period of performance shall be for 12 months starting from the date of award.

### 7.0 PLACE OF PERFORMANCE

Elima Jedy-Agba| MD, MSc., Ph.D.

IRCE Coordinator

International Research Center of Excellence (IRCE) |<http://www.ihvn-irce.org/>

Institute of Human Virology, Nigeria|<http://ihvnigeria.org>

Email: [ejedyagba@ihvnigeria.org](mailto:ejedyagba@ihvnigeria.org); [elima.jedyagba@gmail.com](mailto:elima.jedyagba@gmail.com)

Phone: +2348033404950

### 8.0 REPORT(S)/DELIVERABLES AND DELIVERY SCHEDULE

<i>DELIVERABLE</i>	<i>DELIVERABLE DESCRIPTION / FORMAT REQUIREMENTS</i>	<i>DUE DATE</i>
4.1	Prepare a report on the feasibility as a coordinating center to assemble biospecimens, images, and clinical and epidemiologic data of never-smoking lung cancer cases from sites in Nigeria. The report will include the following information by sites: the available number of never-smoking lung cancer cases, the available number of fresh frozen tumor, normal, and blood tissues, FFPE tumor blocks, chest CT, PET, and x-ray images, and key clinical and epidemiological data, and the expected time frame to delivery the biospecimens and data. It will also include the expected challenges and suggestions for material and data collection.	Months 1-2
4.2	Shipment of an initial batch of following biospecimens for up to 10 never-smoking lung cancer cases retrieved from sites to designated NCI laboratory: a. Fresh frozen tumor tissue (T) >60% tumor cells, <20% necrosis. Multiple samples preferred. If from biopsies, 2 samples of 40 mg each. b. Paired fresh frozen normal tissue (N), no tumor cells. Multiple samples preferred (4 normal specimens if possible). If biopsies, 2 samples of 40 mg each.	Months 6-12

## STATEMENT OF WORK (SOW)

	<ul style="list-style-type: none"> <li>c. Blood (B) 500uL whole blood or buffy coat</li> <li>d. FFPE blocks at least one from tumor center and one from tumor periphery to be sectioned.</li> <li>e. Peri-diagnostic plasma (P), optimal <math>\geq</math> 7ml, minimum <math>\geq</math> 3 ml.</li> </ul>	
4.3	<p>Deliver an initial batch of following de-identified data for each never-smoking lung cancer case retrieved from sites to NCI contact person:</p> <ul style="list-style-type: none"> <li>a. Epidemiologic data in spreadsheets: variables shall include but are not limited to demographics, BMI, occupational and environmental exposures, residential history, family history, medical history and history of lung diseases or other infections.</li> <li>b. Clinical data in spreadsheets: variables shall include but are not limited to clinical stage, histology, grade, survival, recurrence, metastasis and other treatment categories.</li> <li>c. All available chest CT, PET, and x-ray images (if CT and/or PET available, x-ray not required) for each case along with de-identified radiology reports or information abstracted from radiology reports. The images should be transferred via secure web portal or shipped via CD or DVD.</li> <li>d. Pathology reports or information abstracted from pathology reports, delivered electronically or via shipment.</li> </ul>	Months 6-12

### 9.0 PAYMENT

Payment shall be made in 2 payments. Payment authorization requires submission and approval of invoices to the COR and NIH OFM, in accordance with the attached payment provisions listed below:

The following clause is applicable to all Purchase Orders, Task or Delivery Orders, and Blanket Purchase Agreement (BPA) Calls: PROMPT PAYMENT (JUL 2013) FAR 52.232-25. Highlights of this clause and NIH implementation requirements follow:

#### I INVOICE REQUIREMENTS

- A. An invoice is the Contractor's bill or written request for payment under the contract for supplies delivered or services performed. A proper invoice is an "Original" which must

## STATEMENT OF WORK (SOW)

include the items listed in subdivisions 1 through 12, below, in addition to the requirements of FAR 32.9. If the invoice does not comply with these requirements, the Contractor will be notified of the defect within 7 days after the date the designated billing office received the invoice (3 days for meat, meat food products, or fish, and 5 days for perishable agricultural commodities, dairy products, edible fats or oils) with a statement of the reasons why it is not a proper invoice. (See exceptions under II., below.) Untimely notification will be taken into account in the computation of any interest penalty owed the Contractor.

1. Vendor/Contractor: Name, Address, Point of Contact for the invoice (Name, title, telephone number, e-mail and mailing address of point of contact).
2. Remit-to address (Name and complete mailing address to send payment).
3. Remittance name must match exactly with name on original order/contract. If the Remittance name differs from the Legal Business Name, then both names must appear on the invoice.
4. Invoice date.
5. Unique invoice #s for all invoices per vendor regardless of site.
6. NBS document number formats must be included for awards created in the NBS: Contract Number; Purchase Order Number; Task or Delivery Order Number and Source Award Number (e.g., Indefinite Delivery Contract number; General Services Administration number); or, BPA Call Number and BPA Parent Award Number.
7. Data Universal Numbering System (DUNS) or DUNS + 4 as registered in the Central Contractor Registration (CCR).
8. Federal Taxpayer Identification Number (TIN). In those exceptional cases where a contractor does not have a DUNS number or TIN, a Vendor Identification Number (VIN) must be referenced on the invoice. The VIN is the number that appears after the contractor's name on the face page of the award document.
9. Identify that payment is to be made using a three-way match.
10. Description of supplies/services that match the description on the award, by line billed.\*
11. Freight or delivery charge must be billed as shown on the award. If it is included in the item price do not bill it separately. If identified in the award as a separate line item, it must be billed separately.
12. Quantity, Unit of Measure, Unit Price, Extended Price of supplies delivered or services performed, as applicable, and that match the line items specified in the award.\*

\* NOTE: If your invoice must differ from the line items on the award, please contact the Contracting Officer before submitting the invoice. A modification to the order or contract may be needed before the invoice can be submitted and paid.

- B. Shipping costs will be reimbursed only if authorized by the Contract/Purchase Order. If authorized, shipping costs must be itemized. Where shipping costs exceed \$100, the invoice must be supported by a bill of lading or a paid carrier's receipt.
- C. Mail an original and 1 copy of the itemized invoice to:

National Institutes of Health  
Office of Financial Management, Commercial Accounts  
2115 East Jefferson Street, Room 4B-432, MSC 8500  
Bethesda, MD 20892-8500

## STATEMENT OF WORK (SOW)

For inquiries regarding payment call: (301) 496-6088

In order to facilitate the prompt payment of invoices, it is recommended that the vendor submit a photocopy of the invoice to the "Consignee" designated for the acquisition in blocks 6A – 6E of the face page of the Order/Award document.

### II. INVOICE PAYMENT

- A. Except as indicated in paragraph B., below, the due date for making invoice payments by the designated payment office shall be the later of the following two events:
  - 1. The 30th day after the designated billing office has received a proper invoice.
  - 2. The 30th day after Government acceptance of supplies delivered or services performed.
- B. The due date for making invoice payments for meat and meat food products, perishable agricultural commodities, dairy products, and edible fats or oils, shall be in accordance with the Prompt Payment Act, as amended.

### III. INTEREST PENALTIES

- A. An interest penalty shall be paid automatically, if payment is not made by the due date and the conditions listed below are met, if applicable.
  - 1. A proper invoice was received by the designated billing office.
  - 2. A receiving report or other Government documentation authorizing payment was processed and there was no disagreement over quantity, quality, or contractor compliance with a term or condition.
  - 3. In the case of a final invoice for any balance of funds due the contractor for supplies delivered or services performed, the amount was not subject to further settlement actions between the Government and the Contractor.
- B. Determination of interest and penalties due will be made in accordance with the provisions of the Prompt Payment Act, as amended, the Contract Disputes Act, and regulations issued by the Office of Management and Budget.

### IV. PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS, FAR 52.232-40 (DEC 2013)

- a) Upon receipt of accelerated payments from the Government, the Contractor shall make accelerated payments to its small business subcontractors under this contract, to the maximum extent practicable and prior to when such payment is otherwise required under the applicable contract or subcontract, after receipt of a proper invoice and all other required documentation from the small business subcontractor.
- b) The acceleration of payments under this clause does not provide any new rights under the prompt Payment Act.

## **STATEMENT OF WORK (SOW)**

Include the substance of this clause, include this paragraph c, in all subcontracts with small business concerns, including subcontracts with small business concerns for the acquisition of commercial items.

**52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment.**

As prescribed in 4.2105(a), insert the following provision:

REPRESENTATION REGARDING CERTAIN TELECOMMUNICATIONS AND VIDEO SURVEILLANCE SERVICES OR EQUIPMENT (AUG 2019)

(a) Definitions. As used in this provision—

Covered telecommunications equipment or services, Critical technology, and Substantial or essential component have the meanings provided in clause 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment.

(b) Prohibition. Section 889(a)(1)(A) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (Pub. L. 115-232) prohibits the head of an executive agency on or after August 13, 2019, from procuring or obtaining, or extending or renewing a contract to procure or obtain, any equipment, system, or service that uses covered telecommunications equipment or services as a substantial or essential component of any system, or as critical technology as part of any system. Contractors are not prohibited from providing—

- (1) A service that connects to the facilities of a third-party, such as backhaul, roaming, or interconnection arrangements; or
- (2) Telecommunications equipment that cannot route or redirect user data traffic or permit visibility into any user data or packets that such equipment transmits or otherwise handles.

(c) Representation. The Offeror represents that—

It [ ] will, [ ] will not provide covered telecommunications equipment or services to the Government in the performance of any contract, subcontract or other contractual instrument resulting from this solicitation.

(d) Disclosures. If the Offeror has responded affirmatively to the representation in paragraph (c) of this provision, the Offeror shall provide the following information as part of the offer—

- (1) All covered telecommunications equipment and services offered (include brand; model number, such as original equipment manufacturer (OEM) number, manufacturer part number, or wholesaler number; and item description, as applicable);
- (2) Explanation of the proposed use of covered telecommunications equipment and services and any factors relevant to determining if such use would be permissible under the prohibition in paragraph (b) of this provision;
- (3) For services, the entity providing the covered telecommunications services (include entity name, unique entity identifier, and Commercial and Government Entity (CAGE) code, if known); and
- (4) For equipment, the entity that produced the covered telecommunications equipment (include entity name, unique entity identifier, CAGE code, and whether the entity was the OEM or a distributor, if known).

(End of provision)